131 related articles for article (PubMed ID: 36373196)
1. Patients with non-functional metastatic G2 pancreatic neuroendocrine tumor benefit from palliative surgery: A 20-year single-center retrospective analysis.
You T; Tang H; Xu X; Ying H; Sun Z; Cheng Y; Bai C
J Neuroendocrinol; 2022 Dec; 34(12):e13211. PubMed ID: 36373196
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases.
Partelli S; Inama M; Rinke A; Begum N; Valente R; Fendrich V; Tamburrino D; Keck T; Caplin ME; Bartsch D; Thirlwell C; Fusai G; Falconi M
Neuroendocrinology; 2015; 102(1-2):68-76. PubMed ID: 26043944
[TBL] [Abstract][Full Text] [Related]
3. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
5. Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals.
Kıvrak Salim D; Bayram S; Gömceli İ; Çekin AH; Karaca M; Koçer M; Yıldız M
Turk J Gastroenterol; 2019 Oct; 30(10):910-916. PubMed ID: 31625933
[TBL] [Abstract][Full Text] [Related]
6. [Survival and prognostic factors analysis of primitive neuroectodermal tumor].
Shen J; Yuan Y; Hu K; Lian X; Hou XR; Sun S; Yan JF; Liu ZK; Zhang FQ
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):614-618. PubMed ID: 30139033
[No Abstract] [Full Text] [Related]
7. Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients.
Krogh S; Grønbæk H; Knudsen AR; Kissmeyer-Nielsen P; Hummelshøj NE; Dam G
Front Endocrinol (Lausanne); 2022; 13():925632. PubMed ID: 35837305
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and characteristics of pancreatic neuroendocrine tumors: single center experience.
Oh TG; Chung MJ; Park JY; Bang SM; Park SW; Chung JB; Song SY
Yonsei Med J; 2012 Sep; 53(5):944-51. PubMed ID: 22869477
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for pancreatic neuroendocrine neoplasms (pNET) and the risk of small non-functioning pNET.
Lombardi M; De Lio N; Funel N; Sardella C; Russo D; Urbani C; Rossi G; Campani D; Martino E; Marcocci C; Boggi U; Bogazzi F
J Endocrinol Invest; 2015 Jun; 38(6):605-13. PubMed ID: 25501604
[TBL] [Abstract][Full Text] [Related]
11. Palliative Resection of Primary Tumor in Metastatic Nonfunctioning Pancreatic Neuroendocrine Tumors.
Ye H; Xu HL; Shen Q; Zheng Q; Chen P
J Surg Res; 2019 Nov; 243():578-587. PubMed ID: 31031022
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy.
Loosen SH; Kostev K; Eschrich J; Krieg S; Krieg A; Luedde T; Jann H; Roderburg C
Medicine (Baltimore); 2022 Dec; 101(50):e32044. PubMed ID: 36550801
[TBL] [Abstract][Full Text] [Related]
13. Does surgery provide a survival advantage in non-disseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms?
Thornblade LW; Warner SG; Melstrom L; Ituarte PHG; Chang S; Li D; Fong Y; Singh G
Surgery; 2021 Jun; 169(6):1417-1423. PubMed ID: 33637345
[TBL] [Abstract][Full Text] [Related]
14. Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma.
Feng T; Lv W; Yuan M; Shi Z; Zhong H; Ling S
World J Surg Oncol; 2019 Mar; 17(1):54. PubMed ID: 30898132
[TBL] [Abstract][Full Text] [Related]
15. A single-center experience with pancreatic cystic neuroendocrine tumors.
Khalil A; Ewald J; Marchese U; Autret A; Garnier J; Niccoli P; Piana G; Poizat F; Giovannini M; Delpero JR; Turrini O
World J Surg Oncol; 2020 Aug; 18(1):208. PubMed ID: 32799893
[TBL] [Abstract][Full Text] [Related]
16. The prognostic analysis of different metastatic patterns in pancreatic neuroendocrine tumors patients: A population based analysis.
Wang S; Zhang J; Liu S; Zhang J
Medicine (Baltimore); 2019 Nov; 98(44):e17773. PubMed ID: 31689842
[TBL] [Abstract][Full Text] [Related]
17. Identifying Prognostic Factors for Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumours: A Retrospective International Multicentre Cohort Study.
Jiménez-Fonseca P; Krug S; Tamagno G; Fierro Maya F; Monléon Getino A; Rodriguez Casado CI; Costa F; de Herder WW; Jann H
Neuroendocrinology; 2018; 107(4):315-323. PubMed ID: 30025389
[TBL] [Abstract][Full Text] [Related]
18. Decreasing utilization of surgical interventions amongst patients with pancreatic neuroendocrine tumor with liver metastases.
Amini N; Demyan L; Shah M; Standring O; Gazzara E; Lad N; Deperalta DK; Weiss M; Deutsch G
Am J Surg; 2024 Jan; 227():77-84. PubMed ID: 37798150
[TBL] [Abstract][Full Text] [Related]
19. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
20. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
